The European Medicines Agency (EMA) accepts for review Aerie Pharmaceuticals’ (NASDAQ:AERI) marketing application for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The advisory group CHMP should issue an opinion in Q4.
The Phase 3 Mercury 3 study comparing Roclanda to the leading fixed-dose combo product in Europe should be completed in H2, the results of which will support pricing and reimbursement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.